Limits...
Circulating tumour cells and outcome in non-metastatic colorectal cancer: a prospective study.

Bork U, Rahbari NN, Schölch S, Reissfelder C, Kahlert C, Büchler MW, Weitz J, Koch M - Br. J. Cancer (2015)

Bottom Line: No clinicopathological variables were associated with CTC detection in non-metastatic patients.CTC detection (⩾1 CTC per 7.5 ml blood) in the blood was significantly associated with worse overall survival (49.8 vs 38.4 months; P<0.001) in the non-metastatic group (UICC I-III), as well as in the complete cohort (48.4 vs 33.6 months; P<0.001).Preoperative CTC detection is a strong and independent prognostic marker in non-metastatic CRC.

View Article: PubMed Central - PubMed

Affiliation: Department of GI, Thoracic and Vascular Surgery, University Hospital Carl-Gustav-Carus Dresden, Dresden, Germany.

ABSTRACT

Background: Circulating tumour cells (CTC) in the blood have been accepted as a prognostic marker in patients with metastatic colorectal cancer (CRC). Only limited data exist on the prognostic impact of CTC in patients with early stage CRC using standardised detection assays. The aim of this study was to elucidate the role of CTC in patients with non-metastatic CRC.

Methods: A total of 287 patients with potentially curable CRC were enrolled, including 239 patients with UICC stage I-III. CTC were measured in the blood using the CellSearch system preoperatively and on postoperative days 3 and 7. The complete patient group (UICC I-IV) and the non-metastatic cohort (UICC I-III) were analysed independently. Patients were followed for 28 (0-53) months. Prognostic factors for overall and progression-free survival were analysed using univariate and multivariate analyses.

Results: CTC were detected more frequently in patients with metastatic disease. No clinicopathological variables were associated with CTC detection in non-metastatic patients. CTC detection (⩾1 CTC per 7.5 ml blood) in the blood was significantly associated with worse overall survival (49.8 vs 38.4 months; P<0.001) in the non-metastatic group (UICC I-III), as well as in the complete cohort (48.4 vs 33.6 months; P<0.001). On multivariate analysis CTC were the strongest prognostic factor in non-metastatic patients (hazard ratio (HR) 5.5; 95% confidence interval (CI) 2.3-13.6) as well as in the entire study group (HR 5.6; 95% CI 2.6-12.0).

Conclusions: Preoperative CTC detection is a strong and independent prognostic marker in non-metastatic CRC.

Show MeSH

Related in: MedlinePlus

Overall survival and progression-free survival according to presence of at least 1 CTC stratified for the stage of disease. (A–C) Kaplan–Meier estimates of overall survival in patients with UICC stage I–II (A), stage I–III (B) and stage I–IV (C) disease. (D–F) Kaplan–Meier estimates of progression-free survival in patients with UICC stage I–II (D), stage I–III (E) and stage I–IV (F) disease.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4402459&req=5

fig2: Overall survival and progression-free survival according to presence of at least 1 CTC stratified for the stage of disease. (A–C) Kaplan–Meier estimates of overall survival in patients with UICC stage I–II (A), stage I–III (B) and stage I–IV (C) disease. (D–F) Kaplan–Meier estimates of progression-free survival in patients with UICC stage I–II (D), stage I–III (E) and stage I–IV (F) disease.

Mentions: The mean follow-up time was 28 (0–53) months. During the follow-up period, 22 (9.2%) patients died and 23 (9.6%) patients were diagnosed with disease progression in the UICC I–III group. In the complete study group, 40 (13.9%) patients died and 45 (15.7%) patients had disease progression during follow-up (Figure 2).


Circulating tumour cells and outcome in non-metastatic colorectal cancer: a prospective study.

Bork U, Rahbari NN, Schölch S, Reissfelder C, Kahlert C, Büchler MW, Weitz J, Koch M - Br. J. Cancer (2015)

Overall survival and progression-free survival according to presence of at least 1 CTC stratified for the stage of disease. (A–C) Kaplan–Meier estimates of overall survival in patients with UICC stage I–II (A), stage I–III (B) and stage I–IV (C) disease. (D–F) Kaplan–Meier estimates of progression-free survival in patients with UICC stage I–II (D), stage I–III (E) and stage I–IV (F) disease.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4402459&req=5

fig2: Overall survival and progression-free survival according to presence of at least 1 CTC stratified for the stage of disease. (A–C) Kaplan–Meier estimates of overall survival in patients with UICC stage I–II (A), stage I–III (B) and stage I–IV (C) disease. (D–F) Kaplan–Meier estimates of progression-free survival in patients with UICC stage I–II (D), stage I–III (E) and stage I–IV (F) disease.
Mentions: The mean follow-up time was 28 (0–53) months. During the follow-up period, 22 (9.2%) patients died and 23 (9.6%) patients were diagnosed with disease progression in the UICC I–III group. In the complete study group, 40 (13.9%) patients died and 45 (15.7%) patients had disease progression during follow-up (Figure 2).

Bottom Line: No clinicopathological variables were associated with CTC detection in non-metastatic patients.CTC detection (⩾1 CTC per 7.5 ml blood) in the blood was significantly associated with worse overall survival (49.8 vs 38.4 months; P<0.001) in the non-metastatic group (UICC I-III), as well as in the complete cohort (48.4 vs 33.6 months; P<0.001).Preoperative CTC detection is a strong and independent prognostic marker in non-metastatic CRC.

View Article: PubMed Central - PubMed

Affiliation: Department of GI, Thoracic and Vascular Surgery, University Hospital Carl-Gustav-Carus Dresden, Dresden, Germany.

ABSTRACT

Background: Circulating tumour cells (CTC) in the blood have been accepted as a prognostic marker in patients with metastatic colorectal cancer (CRC). Only limited data exist on the prognostic impact of CTC in patients with early stage CRC using standardised detection assays. The aim of this study was to elucidate the role of CTC in patients with non-metastatic CRC.

Methods: A total of 287 patients with potentially curable CRC were enrolled, including 239 patients with UICC stage I-III. CTC were measured in the blood using the CellSearch system preoperatively and on postoperative days 3 and 7. The complete patient group (UICC I-IV) and the non-metastatic cohort (UICC I-III) were analysed independently. Patients were followed for 28 (0-53) months. Prognostic factors for overall and progression-free survival were analysed using univariate and multivariate analyses.

Results: CTC were detected more frequently in patients with metastatic disease. No clinicopathological variables were associated with CTC detection in non-metastatic patients. CTC detection (⩾1 CTC per 7.5 ml blood) in the blood was significantly associated with worse overall survival (49.8 vs 38.4 months; P<0.001) in the non-metastatic group (UICC I-III), as well as in the complete cohort (48.4 vs 33.6 months; P<0.001). On multivariate analysis CTC were the strongest prognostic factor in non-metastatic patients (hazard ratio (HR) 5.5; 95% confidence interval (CI) 2.3-13.6) as well as in the entire study group (HR 5.6; 95% CI 2.6-12.0).

Conclusions: Preoperative CTC detection is a strong and independent prognostic marker in non-metastatic CRC.

Show MeSH
Related in: MedlinePlus